IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The interleukin-6 (IL6)/STAT3 pathway is a key oncogenic pathway in cancer.
• This pathway was previously thought to be functionally linked to estrogen receptor alpha (ER) in breast cancer.
• Understanding the interplay between IL6/STAT3 and ER is crucial for developing effective breast cancer therapies.

Purpose of the Study:

• To investigate the functional relationship between IL6/STAT3 signaling and ER in breast cancer.
• To determine if IL6/STAT3 signaling drives metastasis independently of ER in ER-positive breast cancer.
• To explore the therapeutic potential of targeting the IL6/STAT3 pathway in ER-positive breast cancer.

Main Methods:

• Analysis of IL6/STAT3 and ER signaling pathways in breast cancer models.
• Investigating STAT3's interaction with ER enhancers using molecular biology techniques.
• Evaluating the efficacy of JAK inhibitor ruxolitinib in reducing breast cancer invasion in vivo.

Main Results:

• IL6/STAT3 signaling promotes metastasis in ER-positive breast cancer independent of ER.
• STAT3 utilizes a subset of ER enhancers to activate a unique transcriptional program.
• IL6/STAT3 activity is resistant to standard ER-targeted therapies.
• Ruxolitinib treatment significantly reduces breast cancer invasion in vivo.

Conclusions:

• The IL6/STAT3 and ER oncogenic pathways are functionally distinct in ER-positive breast cancer.
• Targeting STAT3, rather than ER, presents a promising therapeutic strategy.
• IL6/STAT3-targeted therapies hold potential for treating ER-positive breast cancer, particularly in cases resistant to endocrine therapy.